A Phase II Study of Imatinib in Patients with Advanced Anaplastic Thyroid Cancer

Abstract

Imatinib appears to have activity in advanced ATC and is well tolerated. Due to difficulty of accruing patients with a rare malignancy at a single institution, further investigation of imatinib in ATC may be warranted in a multi-institutional setting.